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Abstract The glucagon-like peptide 1 (7-37)/(7-36) amide 
((;LP-1) receptor belongs to a new subclass of seven transmem- 
brane domain, G-protein coupled receptors comprising several 
receptors for peptide hormones. The receptors of this family 
share many common motifs including a relatively large N- 
terminal extracellular domain. The GLP-1 receptor is presently 
attracting much attention, since it is the target protein of the 
antidiabetic gut hormone GLP-I. To establish the functional 
significance of the N-terminal part of the GLP-1 receptor for 
ligand binding, the extracellular domain was isolated and 
purified. Utilizing CHL cells expressing the cloned GLP-1 
receptor, we demonstrate that the isolated, solubilized N- 
terminal part of the receptor protein competes for GLP-1 
binding with the intact wild-type receptor. Moreover, in cross- 
linking experiments radiolabeled GLP-1 was covalently attached 
to the isolated N-terminus, thereby demonstrating direct physical 
interaction of both components. By Western blot analysis two 
specific bands were detectable, representing the N-terminal 
receptor protein in the presence or absence of bound ligand. 
lhese data underline the significance of the N-terminal domain 
of the GLP-1 receptor for ligand binding. 
t, ey words: GLP-1 receptor; N-terminal domain; Intrinsic 
b nding activity 
I Introduction 
Glucagon-like peptide 1 (GLP-1 (7-37)/(7-36) amide) arises 
a~ a post-translation product of the intestinal proglucagon 
gme [1]. GPL-1 potently stimulates glucose-induced insulin 
s,,cretion and proinsulin gene expression [2]. It has therapeutic 
pXential for diabetes mellitus treatment [3]. Recent data have 
demonstrated that injection of GLP-1 into the brain inhibits 
feeding in rats [4]. GLP-1 binding sites are widespread [3] and 
h ave been characterized in pancreatic B cells [5], gastric glands 
[~], lung [7,8] and brain [9]. 
Together with the receptors for vasoactive intestinal poly- 
peptide, pituitary adenylate cyclase activating polypeptide 
(I~ACAP), parathormone, glucagon, gastric inhibitory poly- 
reptide (GIP), and calcitonin, the GLP-1 receptor (GLP-1R) 
belongs to a subclass of seven transmembrane, G-protein 
c mpled receptors (GPCRs) [10]. All members of this family 
(, f GPCRs share a similar basic structure and membrane to- 
pology. In contrast o the superfamily of adrenergic receptors, 
t!tis polypeptide receptor subclass contains a relatively large 
l',-terminal extracellular domain containing highly conserved 
amino acids including 6 cysteine residues. In meticulous tud- 
its, binding sites for agonists and antagonists were defined for 
the adrenergic receptor family, which facilitate the construe- 
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tion of a prototypical seven transmembrane r ceptor model 
[11,12]. In contrast, only a few structure-function analyses 
have been reported for peptide hormone receptors, however, 
a detailed understanding of the molecular mechanisms of the 
ligand-receptor interaction is of outstanding pharmacological 
interest. 
Recent studies revealed evidence for the importance of the 
extracellular N-terminal domain for ligand binding in this 
subclass of GPCRs [13-19]. Point mutation experiments with- 
in the N-terminus of the rat GLP-1 receptor suggested a 
dominant biological function for binding [14]. Utilizing the 
purified, solubilized N-terminal domain of the rat GLP-1 re- 
ceptor (N-T GPL-1R), it could now be demonstrated that this 
part of the receptor exhibits intrinsic ligand binding affinity. 
2. Materials and methods 
2.1. Materials 
Chemicals, all of highest grade, were purchased from Sigma (Dei- 
senhofen, Germany) or Merck (Darmstadt, Germany). Sera, media, 
and other tissue culture reagents were from Gibco Laboratories and 
enzymes were from Boehringer Mannheim (Germany). The cross-link- 
ing reagent disuccinimidyl suberate (DSS) was obtained from Pierce 
Europe (Oud-Bijerland, The Netherlands). 
125I-GPL-I and 12~I-glucagon were prepared as described previously 
[20]; the specific activity of the radiolabel amounted to 2000 Ci/mmol. 
2.2. Cell culture 
CHL (Chinese hamster lymphoblast) cells stably transfected with 
the rat wild-type GLP-1 receptor were grown in RPMI 1640 medium 
supplemented with 10% bovine calf serum, 1 mM sodium pyruvate 
and 1% non-essential mino acids at 37°C in 95°/,, air and 5% CO2. 
2.3. Purification of the N-terminal extracellular domain of the GLP-1 
receptor 
The extracellular domain of the rat GLP-1 receptor without the 
putative leader sequence (amino acids 20-144) was purified by using 
the 6 x His tag system (QIAGEN, Germany). The N-terminus was 
amplified by PCR with specific oligonucleotides generating EcoRI 
and BamHI restriction sites at the 5' and 3' ends of the amplified 
fragment o facilitate subcloning in pQE30 vector (QIAGEN, Ger- 
many). The sequence of the construct (pQE30 N-T GLP-1R) was 
verified by sequencing. This plasmid was transformed into the E. 
coli strain M15 [21]. Positive expression clones were checked by 
screening of small-scale xpression cultures. For the purification of 
large amounts of NT GLP-1R, 500 ml LB broth liquid cultures 
were incubated at 37°C until the OD600nm reached 0.74).9 IPTG (iso- 
propyl-13-D-thiogalactopyranoside) was added to a final concentration 
of 0.5 mM and the culture was allowed to continue growth for 3 h at 
37°C. Cells were harvested by centrifugation. The pellet was resus- 
pended in 1 M urea, 50 mM NaH2PO4, 10 mM Tris, pH 7.9 at 3 vols. 
per g wet weight. Cells were disrupted by lysozyme treatment (1 rag/ 
ml final concentration, incubated on ice for 30 min) followed by 
sonification (10 × 30 s bursts/1 min cooling/200 W, using a Labsonic 
sonifier, B. Braun, Germany). Samples were centrifuged for 20 min at 
12000 xg. 8 ml of a 50% slurry of Ni-NTA resin was added to 8 ml of 
the supernatant and stirred on ice for 60 min. The resin was loaded 
onto a column and washed twice with 80 ml solution buffer (1 M 
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urea, 50 mM NaH2PO4, 10 mM Tris, pH 7.9). The N-T GLP-1R 
protein was eluted with a 20 ml bf a pH 7.5-5.0 gradient in solution 
buffer and 1 ml fractions were analyzed on SDS-PAGE. Purity of N-T 
GLP-1R was checked by silver staining of SDS gels. The majority of 
the protein eluted at pH 5.9. 
Immunization of rabbits was performed by Eurogentec (Belgium). 
The antisera raised yielding polyclonal antibodies were tested accord- 
ing to standard protocols. 
The N-terminal domain of the GIP receptor (N-T GIPR) was pur- 
ified using the pMAL system (New England Biolabs, USA). Briefly, 
the DNA encoding the N-terminal domain of GIP receptor was am- 
plified by PCR, subcloned ownstream of the maltose-binding protein 
(MBP) into the pMAL-c2 vector. The sequence of the construct was 
verified by sequencing. The plasmid was transformed into the E. coli 
strain TB1. Cells were inoculated in LB-broth+2% glucose. At an 
OD600nnl of 0.7, IPTG was added to a final concentration of 0.5 
mM. Proteins were isolated in the same way as described for N-T 
GLP-IR (see above) with the exception that amylase resin was used 
instead of Ni-NTA resin. The fusion protein MBP-N-T GIPR was 
eluted with 5 ml of elution buffer (1 M urea, 50 mM NaH2PO4, 10 
mM Tris, pH 6.5+10 mM maltose). To remove the MBP fusion pro- 
tein, eluted samples were treated with factor Xa for 2 days at 4°C. 
Proteins were separated on a native polyacrylamide gel and N-T 
GIPR was isolated by electroelution using a GE200 Sixpac Gel Eluter 
(Hoefer Scientific Instruments, San Francisco, USA). 
2.4. Binding assay of the purified N-terminal domain of the GLP-1 
receptor 
Transfected cells carrying the rat wild-type GLP-1 receptor were 
detached from culture plates using phosphate-buffered saline (pH 
7.3) containing 1.5 mM EDTA. Cells were centrifuged and resus- 
pended in buffer (2.5 mM Tris-HCl, 120 mM NaC1, 1.2 mM MgSO4, 
5 mM KCI, 15 mM CHaCOONa; pH 7.4) supplemented with 1% 
human serum albumin, 0.1% bacitracin, and 1 mM EDTA. Cells 
were incubated for 30 rain at 37°C with 125I-GLP-1 (20000 cpm) in 
the absence (controls) and presence of 6.5x10 7, 2.6×10 7, or 
1.3 × 10 7 M of the purified extracellular domain. Cells were centri- 
fuged for 5 min at 10000xg (4°C), washed in ice-cold incubation 
buffer and centrifuged again. The cell pellet was counted using a 7- 
counter. As additional control, instead of the extracellular domain of 
the GLP-1 receptor the purified N-terminal part of the related GIP 
receptor as well as bacterial lysozyme were added. To examine 
whether formation of disulfide bridges within the extracellular domain 
is important for hormone binding, 6.5 × 10 -7, 2.6 × 10 7, or 1.3 × 10 -7 
M of the purified protein and 10 -4 M of unlabeled GLP-1, respec- 
tively, were incubated for 10 min at room temperature in the presence 
of 10 mM 13-mercaptoethanol before addition to the binding assay. 
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2.5. Cross-linking experiments with the purified extracellular domain 
Cross-linking experiments were performed as described [22]. Briefly, 
purified protein (1 mg/ml) was resuspended in cross-linking buffer (10 
mM HEPES, 118 mM NaCI, 4.7 mM KC1, 5 mM MgC12, 1 mM 
EGTA, 40 /aM PMSF) containing 0.01% (w/v) bacitracin, and 
0.01% (w/v) human serum albumin, (pH 7.4). The protein was incu- 
bated with ]25I-GLP-1 (~ 2 × 106 cpm) in the absence and presence of 
unlabeled GLP-I(7 36) amide (final concentration 1 p.M) at 20°C for 
30 min. DSS (final concentration 0.1 mM) dissolved in DMSO (final 
concentration 1% (v/v)) was added, and the samples incubated for 10 
min at 20°C. The reaction was stopped by addition of Tris-HCl buffer 
(50 mM Tris-HC1, pH 7.0) containing 1 mM EDTA and 1% SDS. 
Samples were further analyzed by gel electrophoresis (SDS/12% 
PAGE) followed by autoradiography. Dried gels were exposed to 
Kodak type X-Omat AR films at -80°C for up to 5 days with the 
use of a light-intensifying screen. 
3. Results 
3.1. Construction of the solubilized N-terminal domain of the 
GLP-1 receptor 
The N-terminal domain of the GLP-1 receptor consists of 
144 amino acids. Using the corresponding cDNA this part of 
the receptor DNA without the putative leader sequence was 
amplified by PCR and subcloned into a bacterial expression 
vector. The protein termed N-T GLP-1R was overexpressed, 
purified to homogeneity and used for all subsequent experi- 
ments (Fig. 1). 
3.2. Binding activity of the N-terminal domain 
To examine whether the N-terminal domain of the GLP-1 
receptor has intrinsic binding activity this purified solubilized 
protein was used as specific competitor in binding assays. 
CHL cells carrying the wild-type GLP-1 receptor were incu- 
bated with radiolabeled GLP-1 and a range of concentrations 
of the purified N-terminal domain was added. 90% of labeled 
GLP-1 was competitively removed from the wild-type recep- 
tor in the presence of 6.5 x 10 -7 M of solubilized extracellular 
receptor domain. Decreasing the concentrat ion to 2 .6x  10 -7 
and 1.3 X 10 -7 M led to a competit ion activity of 87 and 43%, 
respectively (Fig. 2). 
In order to exclude the possibility that not the solution 
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Fig. I. Schematic representation f the construction of N-T GLP-1R. The corresponding cDNA of the rat wild-type GLP-1 receptor was used 
to amplify the N-terminal domain by PCR. The resulting DNA fragment was cloned into a bacterial expression vector and the overexpressed 
N-T GLP-1R protein was purified. The oligonucleotides u ed are indicated by arrows. Closed circles indicate the putative secretory signal pep- 
tide. 
A. Wilmen et al./FEBS Letters 398 (1996) 43-47 
100 
© 
" 4  
.+-- 
¢]) 
z_ 5o 
5 
_] 
£ 
zvT 
solution buffer ~ 
N-T without N4 lysozyme 
GLF 1R N-T GLP- 1R GIP-R 
Fi ;. 2. Competition ability of the isolated extracellular domain of 
th, GLP-1 receptor. Increasing amounts of the isolated N-terminal 
part of the GLP-I receptor (N-T GLP-1R) were added as competi- 
to in a binding assay using CHL cells expressing the entire wild- 
type GLP-I receptor and 12SI-GLP-I(7-36) amide as radiolabeled 
tr;cer. As controls plain solution buffer without N-T GLP-1R, or 
th. N-terminal domain of the GIP receptor (N-T GIPR), or bacter- 
iai lysozyme were employed. Shown is percent competition vs. con- 
celtration (M) of competitor proteins. • indicates 6.5x10 7, 
2.~.×10 -7, and 1.3x10 7 M protein . Each bar shows the mean 
(_~ S.E.M.) of three or four experiments, each performed in dupli- 
c~ e or triplicate. 
bt~ffer but rather N-T GLP-1R exhibits competition activity, 
th~ experiment was repeated using solution buffer without the 
s(4ubilized protein. The amount of buffer was the same as in 
th~ experiments with N-T GLP-1R. As shown in Fig. 2 the 
selution buffer does not lead to any detectable competition of 
12 I-GLP-1. Therefore, the shift of binding of peptide label 
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suggests attachment to the isolated N-terminus of the recep- 
tor. 
The N-terminal domain of the GIP (gastric inhibitory poly- 
peptide) receptor (N-T GIPR), a close relative of the GLP-1 
receptor (41% homology), was tested as a control for its abil- 
ity to compete within the same assay system. No specific bind- 
ing of GLP-I  to the GIP receptor was detectable [23]. As 
further controls bacterial lysozyme was used. N-T GIPR 
and lysozyme were added to the binding assay in the same 
concentrations as the solubilized extracellu[ar domain of the 
GLP-1 receptor. None of these two proteins showed any com- 
petition activity. This suggested specificity for the ligand bind- 
ing ability of the N-terminal domain of the GLP-I  receptor 
(Fig. 2). 
3.3. The tertiary structure of the extracellular domain is 
important for its competition activity 
Similar to other receptors of the subfamily, the GLP-1 re- 
ceptor contains 6 highly conserved cysteines in the amino- 
terminal domain. Analysis of the related VIP receptor has 
recently shown the importance of these amino acids for ligand 
binding [15]. For the GLP-I  receptor this was studied by 
incubation of N-T GLP-1R with the reducing agent [3-mer- 
captoethanol which induces the complete loss of the disulfide- 
bridge dependent ertiary structure. In order to determine 
whether [3-mercaptoethanol interferes with the binding assay, 
unlabeled ligand (GLP-1) was incubated with the same con- 
centration of reducing agent as the purified N-terminal 
domain. [3-Mercaptoethanol treated GLP-1 showed concen- 
tration-dependent i hibition of t25I-GLP-1 binding to the re- 
ceptor similar to that of the untreated hormone. This indi- 
cated no interference of the reducing agent with the peptide or 
the assay system in general. In contrast, incubation of the 
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Fg. 3. (A) Displacement of 12SI-GLP-l(7-36) amide binding to stably transfected CHL cells by unlabeled GLP-1 treated (e - - e) or not treat- 
et ([] []) with 13-mercaptoethanol. Analysis of the binding data was performed using the PC program Prism (GraphPad, San Diego, 
U5A). (Data are means + S.E.M., (n = 2)). (B) N-T GLP-1P, was treated with 10 mM ~l-mercaptoethanol before being added as competitor in a 
binding assay using CHL cells expressing the entire wild-type GLP-I receptor and 12SI-GLP-l(7-36) amide as radiolabeled tracer. • indicates 
6.~x10 7, 2.6×10-7 and 1.3X10 7 M protein. 
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Fig. 4. (A) Cross-linking of 12SI-GLP-l(7-36) amide to the isolated, solubilized omain of the GLP-1 receptor. The isolated amino terminal do- 
main was incubated in the absence (lane A) and presence (lane B) of 1 gM unlabeled GLP-I(7 36) amide. The complex was crosslinked using 
0.1 mM DSS. In lane C and D N-T GIPR or lysozyme instead of the purified N-terminal part of the GLP-1 receptor was used. Samples were 
separated on SDS/12% PAGE. An autoradiogram of the dried gel is shown. (B) Western blot analysis of the cross-linked N-T GLP-1R/GLP- 
1(7-36) amide complex (lane E). The isolated N-terminal domain of the GLP-1 receptor was cross-linked to unlabeled GLP-I(7 36) amide. Pro- 
teins were separated on SDS/12% PAGE, the gel being blotted onto a nitrocellulose membrane and hybridized with an anti-GLP-1R antibody. 
Two bands are detectable representing the unbound (free N-T GLP-1R, 22 kDa) and the bound (N-T GLP-1R/GLP-1 complex, 28 kDa) N- 
terminal domain of the GLP-1 receptor. The arrows indicate the crosslinked complex and the arrow heads the mobilities of a low range protein 
standard (34.9 kDa = carbonic anhydrase, 28.7 kDa = soybean trypsin inhibitor, 20.5 kDa = lysozyme). 
isolated N-terminal domain with 13-mercaptoethanol led to a 
complete loss of its competition activity (Fig. 3B). 
3.4. Specific interaction between the amino-terminal domain 
and GLP-1 
In order to study the direct physical interaction between 
GLP-1 and the N-terminal domain of the GLP-1 receptor 
the latter was covalently cross-linked to 125I-GLP-1 using 
DSS. After separation of the proteins by SDS PAGE, a single 
ligand-binding protein complex with an apparent molecular 
mass of 28 kDa was detected (Fig. 4A). In control experi- 
ments, a specific band was not found using either the extra- 
cellular part of the GIP receptor or lysozyme. In Western 
analysis employing anti-GLP-1 receptor antibody two bands 
with apparent molecular masses of 22 and 28 kDa, respec- 
tively, were detected representing the N-terminal domain in 
the presence and absence of bound ligand (Fig. 4B). 
4. Discussion 
Our data support he concept hat the extracellular domain 
of peptide hormone receptors contains, at least in part, ele- 
ments for recognizing and binding of corresponding ligands. 
Analysis of chimeras of various receptors upported this hy- 
pothesis [1619]. For example, replacement of the amino- 
terminal domain of the VIP receptor by the homologous re- 
gion from the secretin receptor and vice versa abolished high 
affinity binding [19]. With an alternative xperimental p- 
proach we studied the putative binding affinity of isolated, 
solubilized N-terminal domain of the GLP-1 receptor. 
The present results demonstrate for the first time not only 
competitive activity of the receptor N-terminus (Fig. 2) but 
also hint at a direct physical interaction between GLP-1 and 
the extracellular domain of the GLP-1 receptor. It seems that 
this part of the receptor is a major ligand recognition site. In 
support of our data, it has been reported that a truncated 
form of the PACAP receptor consisting only of the mem- 
brane-anchored extracellular domain showed some binding 
activity [24]. Both approaches uggest hat the N-terminal 
receptor domain alone is already capable of ligand binding 
in this receptor subfamily, although with lower affinity than 
the entire receptor protein. 
Incubation of N-T GLP-1R with 13-mercaptoethanol led to 
complete loss of competition activity. This indicates that the 
correct formation of the tertiary structure of the N-terminal 
domain is a prerequisite for its ligand binding. This is sup- 
ported by a recently published study using mutational analysis 
of the VIP receptor. Here, Gaudin et al. demonstrated that 
cysteine residues within the N-terminal domain are likely to 
be involved in the formation of intramolecular disulfide bonds 
maintaining the structural topology necessary for ligand bind- 
ing [15]. 
The ligand binding ability of solubilized N-terminal recep- 
tor domains may be a physiologically important phenomenon. 
This has been shown earlier for members of the glycoprotein 
receptor family. Isolated receptor N-termini are here naturally 
generated by tissue-specific alternative splicing processes. An 
mRNA encoding the N-terminal domain of the TSH receptor 
was isolated by Graves et al. [25]. Tsai-Morris et al. [26] 
demonstrated that the solubilized form of the extracellular 
domain of the gonadotropin receptor exhibits binding activity 
similar to that of the entire receptor. 
The extracellular domain of the GLP-1 receptor has a low- 
er affinity for GLP-1 binding as the full length receptor. 
This indicates that additional elements of the receptor are 
involved to achieve high affinity ligand binding. In this 
context, it is of interest hat for the PTH receptor Lee et al. 
[27] have shown that in addition to the N-terminal domain 
the third extracellular loop is also involved in PTH(1-34) 
binding. 
In summary, the data presented here demonstrate hat the 
isolated N-terminal domain of the GLP-1 receptor has the 
ability to interact directly with its ligand GLP-1. 
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